Author

A. Hammell

Observed names: Amy B Hammell, Amy B. Hammell

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5001800534

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

2024 · Heinz-Josef Lenz, Aparna Parikh, et al. · Journal for ImmunoTherapy of Cancer · 74

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

2026 · Benjamin Besse, Jessica J. Lin, et al. · Nature Medicine · 23

740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results

2022 · M. Gutierrez, C.F. Friedman, et al. · Annals of Oncology · 2

522P Safety run-in of REPLOT: Phase II repotrectinib plus fulvestrant in HR+/HER2− metastatic invasive lobular carcinoma (mILC) after endocrine therapy (ET) and CDK4/6 inhibition

2026 · J.A. Mouabbi, A. Nwosu Ilheme, et al. · ESMO Open

Works count: 4

Citation count: 98

H-index: 2

I10-index: 2